A guideline for economic evaluations of vaccines and immunization programs in China.
China
Vaccine
economic evaluation
guide
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
30 11 2022
30 11 2022
Historique:
pubmed:
27
10
2022
medline:
15
12
2022
entrez:
26
10
2022
Statut:
ppublish
Résumé
This study aimed to develop a consensus framework for economic evaluations of vaccines as a national guideline in China. Some unique and important aspects were particularly emphasized. Nineteen Chinese experts in the field of health economics and immunization decision-making were nominated to select and discuss relevant aspects of vaccine economic evaluations in China. A workshop attended by external experts was held to summarize unique and important aspects and formulate consensus recommendations. There were ten unique and/or important aspects identified for economic evaluations of vaccines in China, including study perspectives, comparator strategies, analysis types, model choices, costing approaches, utility measures, discounting, uncertainty, equity, and evaluation purposes. Background information and expert recommendations were provided for each aspect. Economic evaluations of vaccines should play an important role in China's immunization policy-making. This guideline can help improve the quality of economic evaluations as a good practice consensus.
Identifiants
pubmed: 36287462
doi: 10.1080/21645515.2022.2132802
pmc: PMC9746533
doi:
Substances chimiques
Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2132802Références
Zhonghua Yu Fang Yi Xue Za Zhi. 2017 Sep 6;51(9):814-820
pubmed: 28881547
Value Health. 2018 Oct;21(10):1133-1149
pubmed: 30314613
BMC Infect Dis. 2017 Jul 18;17(1):502
pubmed: 28720082
Vaccine. 2016 Dec 7;34(50):6158-6165
pubmed: 27838068
Hum Vaccin Immunother. 2022 Jul 11;:2090162
pubmed: 35816415
Pharmacoeconomics. 2016 Mar;34(3):227-44
pubmed: 26477039
Vaccine. 2015 Jun 4;33(24):2830-41
pubmed: 25770785
Vaccine. 2014 Jul 31;32(35):4471-4477
pubmed: 24968160
Hum Vaccin Immunother. 2018 Jun 3;14(6):1444-1452
pubmed: 29425054
Int J Environ Res Public Health. 2017 Jul 11;14(7):
pubmed: 28696387
J R Stat Soc Ser A Stat Soc. 2009 Apr;172(2):383-404
pubmed: 19381329
Vaccine. 2021 Dec 20;39(52):7584-7589
pubmed: 34802784
BMC Infect Dis. 2018 Oct 4;18(1):502
pubmed: 30286735
PLoS One. 2018 Jul 25;13(7):e0201245
pubmed: 30044865
Pharmacoeconomics. 2022 Jan;40(1):45-64
pubmed: 34713423
Lancet Glob Health. 2020 Oct;8(10):e1335-e1344
pubmed: 32971056
PLoS Med. 2016 Mar 15;13(3):e1001975
pubmed: 26978565
Zhonghua Yi Xue Za Zhi. 2021 Jul 13;101(26):2029-2036
pubmed: 34275235
Hum Vaccin Immunother. 2018 Jan 2;14(1):36-44
pubmed: 29049002
Vaccine. 2018 May 17;36(21):3041-3047
pubmed: 29685593
PLoS Negl Trop Dis. 2017 Sep 11;11(9):e0005899
pubmed: 28892475
Vaccine. 2015 Nov 17;33(46):6164-72
pubmed: 26435189
Hum Vaccin Immunother. 2022 Dec 31;18(1):2030623
pubmed: 35176962
Vaccines (Basel). 2021 Mar 03;9(3):
pubmed: 33802327
BMC Med. 2021 Aug 11;19(1):181
pubmed: 34376214
Hum Vaccin Immunother. 2021 Dec 2;17(12):5666-5672
pubmed: 34856877
Hum Vaccin Immunother. 2021 Apr 3;17(4):1073-1082
pubmed: 33269990
Vaccine. 2018 Dec 18;36(52):8131-8137
pubmed: 30497834
Clin Infect Dis. 2009 Oct 15;49(8):1202-10
pubmed: 19739973
Lancet. 2021 Aug 7;398(10299):503-521
pubmed: 34273291
BMC Public Health. 2021 Jun 10;21(1):1118
pubmed: 34112128
Hum Vaccin Immunother. 2020 Jul 2;16(7):1623-1629
pubmed: 32186953
Lancet Reg Health West Pac. 2022 Mar 16;22:100430
pubmed: 35308577
Vaccine. 2016 Apr 19;34(18):2135-40
pubmed: 26917011